In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...